Refractory thrombocytopenia in SLE patient with massive thigh hematoma and hematuria successfully treated with Rituximab: Case Report

Maha J Aljasser, Hanady Manasfi, Amjad Abdelnabi Hanan Y Abdurabu
{"title":"Refractory thrombocytopenia in SLE patient with massive thigh hematoma and hematuria successfully treated with Rituximab: Case Report","authors":"Maha J Aljasser, Hanady Manasfi, Amjad Abdelnabi Hanan Y Abdurabu","doi":"10.4172/1758-4272.1000219","DOIUrl":null,"url":null,"abstract":"Background: Systemic Lupus Erythematosus is a multisystemic inflammatory disease with broad clinical presentation, 9.5% to 44.5% of patients with SLE have thrombocytopenia complication of different grades. No significant increase in risk of hemorrhage was found in patients with SLE with moderate thrombocytopenia, while those with severe thrombocytopenia frequently developed bleeding, which is associated with the activity of the disease and potentially life-threatening condition, if left untreated. Case presentation: We report a case of 35-year-old SLE male patient, presented with sudden painful large non-traumatic ecchymotic lesion on the right thigh extending to calf with macroscopic hematuria. At presentation, platelets count was 50 x 109/L with hemoglobin dropping from 10.3 to 6.9 g/dl. Anticardiolipin antibody and Antiphospholipid antibody were absent. Other factors including infection and visceral involvement were excluded. MRI of the thigh showed huge intramuscular hematoma extending to calf. Satisfactory control was partially achieved with platelet transfusion, pulse steroid, cellcept, IVIG (intravenous immunoglobulins) and consequently Rituximab. Our case describes refractory thrombocytopenia not responding to multiple agents including high dose steroids, cellcept, platelet transfusion, IVIG (intravenous immunoglobulins) and cyklokapron; however, it achieved its complete remission with Rituximab. Bleeding is not usual presentation with moderate thrombocytopenia in SLE patients and presumably played a role in prognosis. Conclusion: Our case report has demonstrated the efficacy of treating refractory thrombocytopenia resistant to steroids due to Systemic Lupus Erythematosus in whom other reasonable options have been exhausted.","PeriodicalId":13740,"journal":{"name":"International Journal of Clinical Rheumatology","volume":"104 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/1758-4272.1000219","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Systemic Lupus Erythematosus is a multisystemic inflammatory disease with broad clinical presentation, 9.5% to 44.5% of patients with SLE have thrombocytopenia complication of different grades. No significant increase in risk of hemorrhage was found in patients with SLE with moderate thrombocytopenia, while those with severe thrombocytopenia frequently developed bleeding, which is associated with the activity of the disease and potentially life-threatening condition, if left untreated. Case presentation: We report a case of 35-year-old SLE male patient, presented with sudden painful large non-traumatic ecchymotic lesion on the right thigh extending to calf with macroscopic hematuria. At presentation, platelets count was 50 x 109/L with hemoglobin dropping from 10.3 to 6.9 g/dl. Anticardiolipin antibody and Antiphospholipid antibody were absent. Other factors including infection and visceral involvement were excluded. MRI of the thigh showed huge intramuscular hematoma extending to calf. Satisfactory control was partially achieved with platelet transfusion, pulse steroid, cellcept, IVIG (intravenous immunoglobulins) and consequently Rituximab. Our case describes refractory thrombocytopenia not responding to multiple agents including high dose steroids, cellcept, platelet transfusion, IVIG (intravenous immunoglobulins) and cyklokapron; however, it achieved its complete remission with Rituximab. Bleeding is not usual presentation with moderate thrombocytopenia in SLE patients and presumably played a role in prognosis. Conclusion: Our case report has demonstrated the efficacy of treating refractory thrombocytopenia resistant to steroids due to Systemic Lupus Erythematosus in whom other reasonable options have been exhausted.
利妥昔单抗治疗难治性血小板减少合并大量大腿血肿和血尿的SLE患者:病例报告
背景:系统性红斑狼疮是一种临床表现广泛的多系统炎症性疾病,9.5% ~ 44.5%的SLE患者有不同程度的血小板减少并发症。伴有中度血小板减少的SLE患者出血风险没有显著增加,而伴有严重血小板减少的SLE患者经常发生出血,如果不及时治疗,出血与疾病的活动性和潜在的危及生命的状况有关。病例介绍:我们报告一例35岁的SLE男性患者,表现为右大腿突然疼痛的非外伤性大瘀斑,并延伸至小腿,伴有肉眼可见的血尿。就诊时,血小板计数为50 × 109/L,血红蛋白从10.3 g/dl降至6.9 g/dl。无抗心磷脂抗体和抗磷脂抗体。其他因素包括感染和内脏受累被排除在外。大腿MRI显示巨大的肌肉内血肿延伸至小腿。通过血小板输注、脉冲类固醇、cellcept、静脉注射免疫球蛋白(IVIG)和随后的利妥昔单抗,部分获得了满意的控制。我们的病例描述了难治性血小板减少症对多种药物无反应,包括大剂量类固醇、塞西普、血小板输注、静脉注射免疫球蛋白(IVIG)和cyklokapron;然而,使用利妥昔单抗后完全缓解。出血在中度血小板减少的SLE患者中并不常见,可能在预后中起作用。结论:我们的病例报告证明了治疗顽固性血小板减少症的有效性,这些顽固性血小板减少症是由于系统性红斑狼疮引起的,其他合理的选择已经用尽。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信